1 / 15

ICIUM 2011 Conference Antalya, Turkey

ICIUM 2011 Conference Antalya, Turkey. 4 th - 18 November 2011. Experiences and use of the MeTA Data Disclosure Survey Tools in GHANA. Daniel Kojo Arhinful No guchi Memorial Institute for Medical Research University of Ghana. Introduction.

preston-mitchell
Download Presentation

ICIUM 2011 Conference Antalya, Turkey

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ICIUM 2011 Conference Antalya, Turkey 4th - 18 November 2011

  2. Experiences and use of the MeTA Data Disclosure Survey Tools in GHANA Daniel Kojo Arhinful No guchi Memorial Institute for Medical Research University of Ghana

  3. Introduction • MeTA’s overall goal is to increase access to essential medicines for the poorest of the poor in developing countries • Ghana and other MeTA pilot countries are developing strategies to promote greater transparency & accountability regarding policies, practices, and outcomes through data disclosure MeTA

  4. Why Disclosure? • Objectives • Enable national MeTA stakeholders to prioritize country activities to facilitate progressive disclosure over time; • Create a baseline against which changes in transparency and disclosure during the MeTA pilot implementation can be measured • Consonance with MeTA’s overall goal to increase access to essential medicines for the poorest in developing countries MeTA

  5. Core areas of Data Disclosure • Medicines registration and quality assurance • Availability of medicines • Price of medicines • Policies and practices concerning the promotion of medicines MeTA

  6. Scope of Information Disclosure • Policies – the laws and regulations that are in place; • Practices – suggested procedures to follow and actual practices; and • Results –achievements in the core area MeTA

  7. Scope of Questions • Policies: Do laws/policies exist? Are they published? Do associated regulations exist? • Practices: Are procedures published? How enforced? Which data exist? Who has access? • Results: Which data are available? Who uses data? Barriers to use? How to promote wider use? MeTA

  8. Process of Data Collection • Tool developed by Harvard Group • Identification of Key Respondents • Questionnaire administered to key Informants • Initial discussion of results by technical sub-group • Re-Visits where necessary to validate results • Discussion of results by Governing Council • Dissemination and discussion by multi-stakeholder Group MeTA

  9. How did the tools fare? Experience and use of the tool MeTA

  10. Policies of Data Disclosure • Do Policies exist? Are they published? Do associated regulations exist? • Very useful in unearthing various policies practices and existing results. Examples of existing policies: • Drug regulation - Food and Drugs Law, P.N.D.C.L 305B, 1992 Customs Excise and Preventive Service (Management) Law 1993; Value Added Tax Act 1998 (Act 546); Public Procurement Act 663 (2003); National Health Insurance Act 2003 (Act 650) and Regulation 2004, (L.I.1809); National Drug Policy (MOH), 2004 MeTA

  11. Are practices published? • YES • Available for sale at Assemblies Press, GPC • Distributed free of charge e.g. Drug Policy • Websites e.g.: http://www.fdbghana.gov.gh/ • http://ghanastandards.org/ • Standard Operating Procedures (SOPs) e.g. • Internal Document not usually in public domain • Egs. • Central Medical Stores Analytical Reports • Tender Procurement Evaluation reports • Quantities and cost of available medicines MeTA

  12. Who has access to existing data? • Everyone? • Law makes it mandatory for anybody to have access but more often…… • Various entities (technical assistance providers and programme implementers, health care providers, regulators, importers, manufacturers, researchers, students, donors & multilateral agencies) MeTA

  13. What are the barriers to disclosure • Culture of non-disclosure despite existing laws & policy • Dealing with sensitivities of various interest groups • Mistrust among stakeholders • Low literacy among the population • Dormant consumer groups • Key websites are not updated regularly • Lack of resources to disseminate widely • Right to Information Bill yet to be passed into legislation

  14. Recommendations on how to promote wider disclosure • Broader engagement of key stakeholders in a very transparent manner • Promote public awareness & education on medicines access • More copies of reports printed to meet increasing demand. • Create more awareness in the media & community groups/CSO • Maintenance of key websites eg. MoH, FDB, GSS & NDIRC

  15. Summary and Conclusions • Data disclosure among multi-stakeholder group provided the following benefits: • Stimulated discussion • Provided grounds to share and learn among various stakeholders • Provided understanding of existing problems • Highlighted challenges for working among multi stakeholder groups • Raised useful questions and led to important recommendations

More Related